Novel Oral Antifungal Treatment for Vulvovaginal Candidiasis
With Jack D. Sobel, MD Dr. Jack Sobel talks about ibrexafungerp, a first-in-class oral triterpenoid antifungal agent approved for the treatment of acute vulvovaginal candidiasis. “Ibrexafungerp (Brexafemme, Scynexis) is a first-in-class oral triterpenoid antifungal agent approved for the treatment of acute vulvovaginal candidiasis (VVC). Post-approval clinical experience is needed to fully understand the optimal use […]